acetic acid, glacial; hydrocortisone; neomycin sulfate - Profile

What are the generic sources for acetic acid, glacial; hydrocortisone; neomycin sulfate and what is the scope of patent protection?

Acetic acid, glacial; hydrocortisone; neomycin sulfate is the generic ingredient in one branded drug marketed by Bayer Pharms and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for acetic acid, glacial; hydrocortisone; neomycin sulfate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for acetic acid, glacial; hydrocortisone; neomycin sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Pharms	NEO-CORT-DOME	acetic acid, glacial; hydrocortisone; neomycin sulfate	SUSPENSION/DROPS;OTIC	050238-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Acetic Acid, Glacial; Hydrocortisone; Neomycin Sulfate: Compound Patent and Market Analysis

Last updated: February 19, 2026

This report analyzes the patent landscape and market fundamentals for the pharmaceutical compound acetic acid, glacial; hydrocortisone; neomycin sulfate. The combination drug is primarily used in otic formulations, addressing bacterial infections and inflammation in the ear. Key patent expirations and the emergence of generic competition significantly impact market dynamics.

What is the primary use of acetic acid, glacial; hydrocortisone; neomycin sulfate?

The combination of acetic acid, glacial; hydrocortisone; and neomycin sulfate is primarily formulated as an otic (ear drop) solution or suspension. Its therapeutic utility stems from the synergistic action of its components.

• Neomycin Sulfate: This is a broad-spectrum aminoglycoside antibiotic effective against a wide range of gram-negative bacteria, including Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae. It functions by inhibiting bacterial protein synthesis, leading to cell death.
• Hydrocortisone: A corticosteroid, hydrocortisone possesses anti-inflammatory, antipruritic (anti-itch), and vasoconstrictive properties. In otic preparations, it reduces swelling, redness, and pain associated with ear canal inflammation and infection.
• Acetic Acid, Glacial: This organic acid acts as a preservative and also has mild antiseptic properties. At the concentrations used in otic preparations, it helps to maintain an acidic pH environment, which can inhibit the growth of certain bacteria and fungi.

Together, these agents target the underlying causes of common ear conditions such as acute otitis externa (swimmer's ear), which is often a bacterial infection accompanied by inflammation.

What is the patent status of acetic acid, glacial; hydrocortisone; neomycin sulfate formulations?

The patent landscape for acetic acid, glacial; hydrocortisone; neomycin sulfate is characterized by expired primary composition-of-matter patents and the ongoing relevance of formulation and method-of-use patents. As the active pharmaceutical ingredients themselves are well-established and their combination has been known for decades, the original patents covering the core drug substance have long since expired.

Key Patent Expiration Dates

Original patents protecting the discovery and initial development of neomycin, hydrocortisone, and acetic acid as standalone therapeutic agents expired many years ago. Patents covering specific fixed-dose combination formulations, however, would have had later expiration dates. Pinpointing exact expiration dates for every potential formulation patent is complex, as numerous patents may have been filed and granted for incremental improvements or specific delivery systems.

For a prevalent brand-name formulation, such as Cortisporin Otic (which contains these active ingredients, along with polymyxin B sulfate), the foundational patents have expired. For instance, patents related to early formulations of neomycin and hydrocortisone were filed in the mid-20th century. The specific combination of neomycin sulfate, hydrocortisone, and acetic acid for otic use has been available since the 1950s and 1960s.

A search of the United States Patent and Trademark Office (USPTO) database reveals numerous patents related to otic compositions and methods of treatment involving these active ingredients. However, the core patents enabling the widespread use of this combination are no longer in force.

• Example of Patent Timeline: While not specific to the precise combination, foundational patents for neomycin (e.g., U.S. Patent 2,916,403 for a fermentation process) were granted in the late 1950s. Hydrocortisone patents date back even earlier. Patents covering the combination would have been filed subsequently, with expiration typically 20 years from the filing date, subject to extensions. Most of these have expired.

Current Patent Landscape

The current patent activity relevant to this drug combination is more likely to focus on:

• Novel Formulations: Patents may cover specific excipients, stabilizers, or delivery mechanisms that enhance drug stability, bioavailability, or patient compliance. This could include specific viscosity modifiers, pH control systems, or controlled-release technologies.
• Manufacturing Processes: Improvements in the synthesis or purification of the active ingredients or the final drug product can be patentable.
• Methods of Use: New indications or specific treatment regimens for otic conditions might be protected by method-of-use patents, although demonstrating novelty and non-obviousness for an established combination can be challenging.
• Dosage Forms: Patents might exist for specific dosage forms or devices for administering the otic solution or suspension.

The absence of strong, overarching composition-of-matter patents for the core combination is a critical factor in the drug's market accessibility.

What are the market fundamentals and competitive landscape for this drug combination?

The market for acetic acid, glacial; hydrocortisone; neomycin sulfate is mature and heavily influenced by generic competition following patent expiries.

Market Size and Growth

The otic anti-infective and anti-inflammatory market segment is substantial, driven by the prevalence of ear infections, particularly in pediatric populations. While precise market size figures for this specific combination are difficult to isolate due to its availability as both a branded and generic product, the overall otic anti-infective market is estimated to be in the hundreds of millions of dollars annually.

Growth drivers include:

• Prevalence of Otitis Externa: Conditions like swimmer's ear, often linked to environmental factors and water exposure, contribute to consistent demand.
• Pediatric Healthcare: Children are particularly susceptible to ear infections, ensuring a stable patient base.
• Chronic Ear Conditions: Management of recurrent or chronic ear inflammation also drives demand.

However, market growth for established, off-patent drugs like this combination is typically modest, often in the low single digits, and largely driven by price adjustments and increased volume of generic sales.

Competitive Landscape

The primary competition comes from generic manufacturers. Once brand-name patents expire, multiple companies can produce and market bioequivalent versions of the drug, leading to significant price erosion.

Key Competitors:

• Branded Product: Historically, Cortisporin Otic (marketed by Bausch Health Companies) has been a dominant brand.
• Generic Manufacturers: A multitude of pharmaceutical companies manufacture generic versions, including but not limited to:
  • Teva Pharmaceuticals
  • Aurobindo Pharma
  • Mylan (now Viatris)
  • Dr. Reddy's Laboratories
  • Hikma Pharmaceuticals
  • Major retail pharmacy brands (e.g., CVS, Walgreens) often have their own private-label generic versions.

Competitive Dynamics:

• Price Sensitivity: The market is highly price-sensitive. Generic products compete primarily on cost.
• Formulation Variations: While the active ingredients are standard, minor differences in excipients or formulations between generic products may exist, though they must meet strict bioequivalence standards.
• Distribution Channels: Availability through major wholesalers, pharmacies, and healthcare systems is crucial.
• Physician Prescription Habits: Prescribing patterns are influenced by familiarity with branded products, physician preference for specific generics, and formulary restrictions imposed by insurance providers.

Pricing and Reimbursement

• Brand-Name Pricing: Branded versions typically command a premium price, reflecting R&D investment, marketing, and established brand recognition.
• Generic Pricing: Generic prices are significantly lower and tend to decline further with increased market penetration and competition.
• Reimbursement: The drug combination is generally covered by most insurance plans, with reimbursement levels varying based on whether a branded or generic product is prescribed and the specific plan's formulary. Medicare and Medicaid also cover medically necessary treatments.

The ongoing presence of multiple generic manufacturers ensures a competitive pricing environment and broad accessibility for patients.

What are the risks and opportunities associated with this drug combination?

The mature nature of acetic acid, glacial; hydrocortisone; neomycin sulfate as a pharmaceutical product presents both inherent risks and limited opportunities for stakeholders.

Risks

• Generic Erosion: The most significant risk is the continued and intense price competition from generic alternatives. Profit margins for branded manufacturers are significantly compressed once generics enter the market.
• Market Saturation: The otic market for this indication is well-established with many therapeutic options, including other antibiotic-steroid combinations and monotherapies.
• Regulatory Scrutiny: Like all pharmaceuticals, the drug is subject to ongoing regulatory oversight by agencies such as the U.S. Food and Drug Administration (FDA) regarding manufacturing quality, labeling, and post-market surveillance.
• Emergence of Novel Therapies: Development of new antimicrobial agents or anti-inflammatory drugs with improved efficacy, safety profiles, or novel mechanisms of action could displace existing treatments.
• Antimicrobial Resistance: While neomycin is an older antibiotic, the growing global concern over antimicrobial resistance could lead to increased caution in its use or the preference for newer agents, though this is less of a concern for localized otic infections.
• Supply Chain Disruptions: As with any drug, the supply chain for raw materials and finished products can be vulnerable to global events, impacting availability and cost.

Opportunities

• Cost-Effective Treatment: For healthcare systems and patients, the availability of affordable generic versions presents an opportunity for significant cost savings in managing ear infections.
• Pediatric Market Dominance: The combination remains a cornerstone therapy for common pediatric ear infections, ensuring a consistent demand.
• Formulation Innovation (Niche): While major patentable innovations are unlikely for the core combination, there may be opportunities for niche formulation improvements that enhance stability, reduce irritation, or improve ease of administration, potentially commanding a slight premium or securing a specific market segment. For example, a preservative-free formulation or a specific viscosity profile.
• Emerging Markets: Expansion into emerging markets where access to advanced healthcare infrastructure might be limited could present growth opportunities, provided the drug can be manufactured and distributed cost-effectively.
• Combination Product Strategy: For companies that manufacture both branded and generic versions, the opportunity lies in leveraging their manufacturing and distribution networks to capture market share across different price points.

The primary opportunity lies in efficient manufacturing and distribution to serve the high-volume, cost-sensitive generic market.

What are the regulatory considerations for acetic acid, glacial; hydrocortisone; neomycin sulfate?

Regulatory compliance is paramount for the manufacturing, marketing, and distribution of acetic acid, glacial; hydrocortisone; neomycin sulfate. Agencies like the U.S. Food and Drug Administration (FDA) oversee these aspects.

FDA Approval and Oversight

• New Drug Application (NDA) / Abbreviated New Drug Application (ANDA): The original branded product would have undergone a rigorous NDA process, demonstrating safety and efficacy. Generic versions require an ANDA, proving bioequivalence to the reference listed drug (RLD) and meeting manufacturing standards.
• Current Good Manufacturing Practices (cGMP): All facilities involved in the manufacturing of the active pharmaceutical ingredients (APIs) and the finished drug product must adhere to strict cGMP regulations. This ensures product quality, consistency, and safety. Inspections by the FDA are routine.
• Labeling Requirements: Prescribing information, patient information leaflets, and product labeling must be accurate, comprehensive, and comply with FDA guidelines. This includes details on indications, contraindications, warnings, precautions, adverse reactions, and dosage.
• Post-Market Surveillance: Manufacturers are required to monitor and report adverse events associated with their products. The FDA also conducts surveillance and may request product recalls or manufacturing changes if safety concerns arise.
• Drug Master Files (DMFs): Manufacturers of APIs typically file DMFs with the FDA, which contain proprietary information about the manufacturing process, facilities, and quality controls. These are referenced by ANDA holders.

Specific Considerations for the Combination

• Stability Testing: The combination of active ingredients requires thorough stability testing under various conditions to determine shelf-life and ensure the potency of each component remains within acceptable limits throughout the product's expiration date. Acetic acid's role in pH adjustment is critical for the stability of other components.
• Sterility: Otic preparations must be sterile to prevent ocular infections. Manufacturing processes must ensure the absence of microbial contamination.
• Bioequivalence Studies: For generic ANDAs, extensive bioequivalence studies are required to demonstrate that the generic product performs comparably to the RLD in terms of absorption, distribution, metabolism, and excretion.

International Regulatory Harmonization

While FDA regulations are primary for the U.S. market, manufacturers often need to comply with the regulations of other countries if they intend to market the drug internationally. Harmonization efforts through bodies like the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) aim to streamline these processes.

Key Takeaways

The pharmaceutical compound acetic acid, glacial; hydrocortisone; neomycin sulfate is an established otic therapeutic agent with a mature market characterized by significant generic competition. Primary composition-of-matter patents have long expired, with current patent activity focusing on formulation enhancements and manufacturing processes. The market fundamentals are driven by the prevalence of otitis externa, particularly in pediatric populations, and are dominated by price-sensitive generic manufacturers. Risks include intense generic erosion and market saturation, while opportunities lie in cost-effective generic provision and potential niche formulation improvements. Strict adherence to regulatory standards, including cGMP and bioequivalence requirements, is essential for all manufacturers.

Frequently Asked Questions

1. Are there any new patent applications currently protecting this specific drug combination? While foundational patents for the active ingredients and their combination have expired, new patent applications may exist for novel formulations, improved delivery systems, or specific manufacturing processes that offer distinct advantages. However, significant patent protection for the core composition is unlikely.

2. How does the price of generic acetic acid, glacial; hydrocortisone; neomycin sulfate compare to the branded version? Generic versions are substantially less expensive than the branded product. The price difference can range from 50% to over 90%, reflecting the competitive nature of the generic market post-patent expiry.

3. What are the main side effects associated with this drug combination? Common side effects include local irritation, burning, itching, redness, or stinging at the application site. Allergic reactions to neomycin are possible. Hydrocortisone can, with prolonged or excessive use, lead to thinning of the skin or other corticosteroid-related side effects, though this is less common with topical otic application.

4. Can this drug combination be used for fungal ear infections? While acetic acid has mild antiseptic properties, this combination is primarily designed to treat bacterial infections. It is not typically considered a first-line treatment for fungal ear infections. Specific antifungal agents would be required for such conditions.

5. What is the shelf-life of this drug combination once opened? The shelf-life of the opened product depends on the specific formulation and manufacturer's recommendations. Typically, opened otic solutions or suspensions should be used within a specified period, often 2-4 weeks, to maintain sterility and potency. Patients should refer to the product packaging or consult their pharmacist.

---

Citations

[1] U.S. Patent No. 2,916,403 (filed June 3, 1957). [2] Bausch Health Companies. (n.d.). Cortisporin® Otic Product Information. Retrieved from Bausch Health website. [3] U.S. Food and Drug Administration. (n.d.). Abbreviated New Drug Applications (ANDAs). Retrieved from FDA website. [4] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from FDA website.